Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.

Mauro FR, Paoloni F, Molica S, Reda G, Trentin L, Sportoletti P, Marchetti M, Pietrasanta D, Marasca R, Gaidano G, Coscia M, Stelitano C, Mannina D, Di Renzo N, Ilariucci F, Liberati AM, Orsucci L, Re F, Tani M, Musuraca G, Gottardi D, Zinzani PL, Gozzetti A, Molinari A, Gentile M, Chiarenza A, Laurenti L, Varettoni M, Ibatici A, Murru R, Ruocco V, Del Giudice I, De Propris MS, Della Starza I, Raponi S, Nanni M, Fazi P, Neri A, Guarini A, Rigolin GM, Piciocchi A, Cuneo A, Foà R.

Open source

DOI
10.3390/cancers14010207
Published
2021-12-31
Container
Cancers (Basel)
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/cancers14010207,
  title = {Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.},
  author = {Mauro FR and  Paoloni F and  Molica S and  Reda G and  Trentin L and  Sportoletti P and  Marchetti M and  Pietrasanta D and  Marasca R and  Gaidano G and  Coscia M and  Stelitano C and  Mannina D and  Di Renzo N and  Ilariucci F and  Liberati AM and  Orsucci L and  Re F and  Tani M and  Musuraca G and  Gottardi D and  Zinzani PL and  Gozzetti A and  Molinari A and  Gentile M and  Chiarenza A and  Laurenti L and  Varettoni M and  Ibatici A and  Murru R and  Ruocco V and  Del Giudice I and  De Propris MS and  Della Starza I and  Raponi S and  Nanni M and  Fazi P and  Neri A and  Guarini A and  Rigolin GM and  Piciocchi A and  Cuneo A and  Foà R.},
  year = {2021},
  journal = {Cancers (Basel)},
  doi = {10.3390/cancers14010207},
  url = {https://doi.org/10.3390/cancers14010207}
}

RIS

TY  - JOUR
TI  - Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.
AU  - Mauro FR
AU  -  Paoloni F
AU  -  Molica S
AU  -  Reda G
AU  -  Trentin L
AU  -  Sportoletti P
AU  -  Marchetti M
AU  -  Pietrasanta D
AU  -  Marasca R
AU  -  Gaidano G
AU  -  Coscia M
AU  -  Stelitano C
AU  -  Mannina D
AU  -  Di Renzo N
AU  -  Ilariucci F
AU  -  Liberati AM
AU  -  Orsucci L
AU  -  Re F
AU  -  Tani M
AU  -  Musuraca G
AU  -  Gottardi D
AU  -  Zinzani PL
AU  -  Gozzetti A
AU  -  Molinari A
AU  -  Gentile M
AU  -  Chiarenza A
AU  -  Laurenti L
AU  -  Varettoni M
AU  -  Ibatici A
AU  -  Murru R
AU  -  Ruocco V
AU  -  Del Giudice I
AU  -  De Propris MS
AU  -  Della Starza I
AU  -  Raponi S
AU  -  Nanni M
AU  -  Fazi P
AU  -  Neri A
AU  -  Guarini A
AU  -  Rigolin GM
AU  -  Piciocchi A
AU  -  Cuneo A
AU  -  Foà R.
PY  - 2021
JO  - Cancers (Basel)
DO  - 10.3390/cancers14010207
UR  - https://doi.org/10.3390/cancers14010207
ER  -

APA

FR, M., F, P., S, M., G, R., L, T., P, S., M, M., D, P., R, M., G, G., M, C., C, S., D, M., N, D. R., F, I., AM, L., L, O., F, R., M, T., G, M., D, G., PL, Z., A, G., A, M., M, G., A, C., L, L., M, V., A, I., R, M., V, R., I, D. G., MS, D. P., I, D. S., S, R., M, N., P, F., A, N., A, G., GM, R., A, P., A, C., & R., F. (2021). Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.. Cancers (Basel). https://doi.org/10.3390/cancers14010207

Source records